ISR - Earnings announcements

RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) (NYSE:ISR), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, today announced unaudited financial results for the three months ended December 31, 2022. "The fourth quarter represented a transformational period leading up to the completed merger between Isoray and Viewpoint Molecular Targeting. In the Company's core brachytherapy business lack of orders from our largest customer and post-COVID recovery

RICHLAND, Wash., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the first quarter fiscal 2023 ended September 30, 2022 and provided updates regarding the pending merger with Viewpoint Molecular Targeting. Isoray CEO Lori Woods said the pending merger signifies a watershed moment in the evolution of the company. "The pending merger represents an exciting transformational opportunity for Isoray and all our stakeholders. It provides us with the opportunity to build on Isoray's existing business with a pipeline of very

RICHLAND, Wash., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial results for the first quarter fiscal 2023 ended September 30, 2022 on Thursday, November 10, 2022, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the first quarter fiscal year 2023 after the close of the U.S. stock markets on November 10, 2022. To listen to the conference call, please dial (877) 545-0320. For callers outside the U.S., please dial (973) 528-0002

RICHLAND, Wash., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy, today announced that it has entered into a definitive agreement to acquire Viewpoint Molecular Targeting, Inc. (Viewpoint) a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents. Under the terms of the agreement, a newly formed wholly owned subsidiary of Isoray will merge with and into Viewpoint, with Viewpoint becoming a wholly owned subsidiary of Isoray. At the effective time of the merger, each issued and outstanding share of common stock of Viewpoint will be converted into the right to r

RICHLAND, Wash., Sept. 21, 2022 (GLOBE NEWSWIRE) --  Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call to discuss its financial results for the fourth quarter and fiscal year ended June 30, 2022 on Wednesday, September 28, 2022, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the fourth quarter and fiscal year ended June 30, 2022 after the close of the U.S. stock markets on September 28, 2022. To listen to the conference call, please dial 888-506-0062. For callers outside the U.S., please dial 973-528-0011. The conference call will be

Revenue Increased 12% Year-Over-YearRecord Non-Prostate Brachytherapy Revenue Increased 28% Year-Over-Year RICHLAND, Wash., May 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy, today announced its financial results for the third quarter of fiscal 2022 ended March 31, 2022. Revenue for the third quarter of fiscal 2022 grew 12% to $2.91 million versus $2.60 million in the prior year comparable period. The Company's core prostate brachytherapy revenue increased 8% versus the third quarter of fiscal 2021. Prostate brachytherapy represented 75% of total revenue for the third quarter of fiscal 2022 compared to 78% in the pr

RICHLAND, Wash., April 29, 2022 (GLOBE NEWSWIRE) --  Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call to discuss its financial results for the third quarter fiscal 2022 ended March 31, 2022 on Tuesday, May 10, 2022, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the third quarter fiscal year 2022 after the close of the U.S. stock markets on Tuesday, May 10, 2022. To listen to the conference call, please dial (888) 506-0062. For callers outside the U.S., please dial (973) 528-0011. The conference call will be simultaneously webcast and c

Revenue Increased 19% Year-Over-YearProstate Brachytherapy Revenue Increased 13% Year-Over-Year RICHLAND, Wash., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy, today announced its financial results for the second quarter of fiscal 2022 ended December 31, 2021. Revenue for the second quarter of fiscal 2022 grew 19% to $2.82 million versus $2.36 million in the prior year comparable period. The Company's core prostate brachytherapy revenue increased 13% versus the second quarter of fiscal 2021. Prostate brachytherapy represented 76% of total revenue for the second quarter of fiscal 2022 compared to 80% in the prio

RICHLAND, Wash., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call to discuss its financial results for the second quarter fiscal 2022 ended December 31, 2021 on Tuesday, February 8, 2022, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the second quarter fiscal year 2022 after the close of the U.S. stock markets on Tuesday, February 8, 2022. To listen to the conference call, please dial (888) 506-0062. For callers outside the U.S., please dial (973) 528-0011. The conference call will be simultaneously webcas

Prostate Revenue Increased Year-Over-Year for Second Consecutive QuarterNon-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year RICHLAND, Wash., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the first quarter fiscal 2022 ended September 30, 2021. Revenue for the first quarter of fiscal 2022 grew 8% to $2.56 million versus $2.38 million in the prior year comparable period. The company's core prostate brachytherapy revenue increased 4% versus the first quarter of fiscal 2021. Prostate brachytherapy represen

RICHLAND, Wash. , Oct. 29, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial results for the first quarter fiscal 2022 ended September 30, 2021 on Wednesday, November 10, 2021, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the first quarter fiscal year 2022 after the close of the U.S. stock markets on November 10, 2021. To listen to the conference call, please dial (888) 506-0062. For callers outside the U.S., please dial (973) 528-00

RICHLAND, Wash., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, will host a rescheduled conference call to discuss its financial results for the fourth quarter and fiscal year ended June 30, 2021 on Wednesday, September 22, 2021, at 10:00 a.m. Eastern Time/7:00 a.m. Pacific. The rescheduled conference call was necessitated by the conference bridge provider's technical failure. The Company has already issued a press release announcing its financial results for the fourth quarter and fiscal year ended June 30, 2021. The press release was issued after the close

Record Full Year RevenueFiscal Fourth Quarter Revenue Increased 19% Year-Over-Year RICHLAND, Wash., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced financial results for the fiscal fourth quarter and full-year ended June 30, 2021. Revenue for the fourth quarter of fiscal 2021 grew 19% to $2.71 million versus $2.28 million in the prior year comparable period. The Company's core prostate brachytherapy revenue grew 5% when compared to the fiscal fourth quarter of 2020. Prostate brachytherapy represented 74% of total revenue for the fourth qua

RICHLAND, Wash, Sept. 09, 2021 (GLOBE NEWSWIRE) --  – Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial results for the fourth quarter and fiscal year ended June 30, 2021 on Tuesday, September 21, 2021, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the fourth quarter and fiscal year ended June 30, 2021 after the close of the U.S. stock markets on September 21, 2021. To listen to the conference call, please dial 844-369-8770. For callers outside the U.S., please

Revenue Increased 10% Sequentially Record Non-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year RICHLAND, Wash., May 13, 2021 (GLOBE NEWSWIRE) --  Isoray, Inc. (NYSE:ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the third quarter fiscal 2021 ended March 31, 2021. Revenue for the third quarter of fiscal 2021 declined 10% to $2.60 million versus the record $2.88 million in the prior year comparable period. Revenue increased 10% sequentially from the fiscal second quarter ended December 31,2020. The company's core prostate brachytherapy revenue declined 16%